Screening adults with obesity for heart failure risks
Screening Adults With Obesity to Reduce Heart Failure Events
This study tests if checking for early signs of heart failure in adults aged 45 and older with obesity can help them get better treatment and improve their health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 420 (estimated) |
| Ages | 45 Years and up |
| Sex | All |
| Sponsor | Franciscus Gasthuis Academic / other |
| Locations | 1 site (Rotterdam) |
| Trial ID | NCT06137261 on ClinicalTrials.gov |
What this trial studies
This study investigates whether active screening for early signs of heart failure (HF) and its risk factors in adults with obesity improves clinical outcomes. It targets individuals aged 45 and older with a body mass index (BMI) of 30 kg/m2 or higher, who do not have known cardiac disease. The study employs a randomized controlled design to assess the effectiveness of screening in identifying HF risks and initiating early treatment, potentially enhancing quality of life and reducing morbidity and mortality associated with heart failure.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 45 and older with obesity (BMI ≥30 kg/m2) who do not have known cardiac disease.
Not a fit: Patients with known cardiac disease or those currently receiving weight-reducing medication may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection and treatment of heart failure in obese patients, improving their overall health outcomes.
How similar studies have performed: While there is limited data on similar screening approaches in this specific population, the rationale is supported by unpublished findings indicating a significant prevalence of undiagnosed heart failure among obese individuals.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥45 year * BMI ≥30 kg/m2 * Written informed consent. Exclusion Criteria: * Known cardiac disease (determined by asking the patient and by assessment of the available patient files). * Treatment with weight-reducing medication.
Where this trial is running
Rotterdam
- Franciscus Gasthuis & Vlietland — Rotterdam, Netherlands (Recruiting)
Study contacts
- Principal investigator: Bas M van Dalen, Dr. — Franciscus Gasthuis & Vlietland
- Study coordinator: Bas M van Dalen, Dr.
- Email: b.vandalen@franciscus.nl
- Phone: 0031104616139
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.